Novartis will integrate the pharmaceuticals and oncology business units and create two separate commercial organizations with a stronger geographic focus — Innovative Medicines U.S. and Innovative Medicines International.
The initiative is designed to reduce care gaps and improve care management and coordination by providing access to more affordable and convenient services in the communities where Blue Shield members live.
Triumeq, the first dispersible single-tablet regimen containing dolutegravir, increases age-appropriate treatment options for children living with HIV, the company said.
